NetworkNewsBreaks – Predictive Oncology (NASDAQ:
Post# of 281
(Total Views: 178)
Posted On: 01/27/2021 3:48:40 PM
NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $4.1 Million
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970 shares of POAI’s common stock, offered at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules. The announcement noted that gross proceeds from this offering for Predictive Oncology will total approximately $4.1 million, before fees and other offering expenses are deducted. POAI anticipates using net proceeds from the offering for working capital projects and purposes. The company also announced a concurrent private placement. That placement was issued to the same investors and was comprised of unregistered warrants to purchase up to 1,707,485 shares of common stock at an exercise price of $1.37 per share. The warrants have a five-and-one-half-year term. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970 shares of POAI’s common stock, offered at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules. The announcement noted that gross proceeds from this offering for Predictive Oncology will total approximately $4.1 million, before fees and other offering expenses are deducted. POAI anticipates using net proceeds from the offering for working capital projects and purposes. The company also announced a concurrent private placement. That placement was issued to the same investors and was comprised of unregistered warrants to purchase up to 1,707,485 shares of common stock at an exercise price of $1.37 per share. The warrants have a five-and-one-half-year term. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Predictive Oncology Inc. (POAI) Stock Research Links
Scroll down for more posts ▼